Dose-Response to Resistance Exercise on Cardiovascular Health

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40+
SponsorUniversity of Pittsburgh

About this trial

A large body of evidence indicates numerous health benefits of physical activity, including prevention of cardiovascular disease (CVD), the leading cause of death in the US. This evidence has led to US Physical Activity Guidelines that recommend ≥150 min/week of moderate or ≥75 min/week of vigorous aerobic exercise (AE), plus resistance exercise (RE; such as weight lifting) on ≥2 days/week. To date, current research has mostly focused on AE, and we know a great deal about the dose-response relation between AE and health, resulting in clear and practical guidance to the public on the recommended "dose" in min/week. However, currently far less is known about the dose-response for RE: ≥2 days/week are recommended, but with no duration specified. Thus, this project aims to provide clarity on the dose relationship between RE and health. This project will significantly contribute to developing more effective CVD prevention approaches, advancing prescriptive intervention guidelines, by helping to fill the important gaps in knowledge on effective minimum dose, beneficial optimal dose, and safe maximum dose of RE for CVD prevention. Thus, advancing prescriptive intervention guidelines, and provide important insights for future science of physical activity and health.

Eligibility criteria

Qualifiers

Non-Smoker

Overweight or Obese: Body Mass Index 25-43 kg/m2

Inactive: not meeting the US resistance and aerobic exercise guidelines over the last 6 months

Walking <7,000 steps/day at baseline

Disqualifiers

Unstable coronary heart disease or heart failure

Uncontrolled arrhythmias or severe aortic stenosis

Acute myocarditis, endocarditis, or pericarditis

Cancer, requiring treatment in the past 5 years

Trial design

Treatments tested in this trial

  • Aerobic exercise only
  • 30 min of resistance exercise
  • 60 min of resistance exercise
  • 120 min of resistance exercise

Treatment groups

240 Participants
are divided into 4 treatment groups

Sponsors and collaborators

University of Pittsburgh

Lead sponsor

University of California, Riverside

Collaborator

Iowa State University

Collaborator

Harvard School of Public Health (HSPH)

Collaborator

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator